This HTML5 document contains 105 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dbpedia-dehttp://de.dbpedia.org/resource/
dcthttp://purl.org/dc/terms/
dbohttp://dbpedia.org/ontology/
foafhttp://xmlns.com/foaf/0.1/
n20https://global.dbpedia.org/id/
dbthttp://dbpedia.org/resource/Template:
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
n8http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#
n9https://www.nature.com/articles/
n14http://commons.wikimedia.org/wiki/Special:FilePath/
dbpedia-fahttp://fa.dbpedia.org/resource/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
wikipedia-enhttp://en.wikipedia.org/wiki/
dbchttp://dbpedia.org/resource/Category:
dbphttp://dbpedia.org/property/
provhttp://www.w3.org/ns/prov#
xsdhhttp://www.w3.org/2001/XMLSchema#
wikidatahttp://www.wikidata.org/entity/
dbrhttp://dbpedia.org/resource/

Statements

Subject Item
dbr:Intellia_Therapeutics
rdf:type
n8:SocialPerson n8:Agent owl:Thing dbo:Agent dbo:Company schema:Organization wikidata:Q4830453 wikidata:Q43229 wikidata:Q24229398 dbo:Organisation
rdfs:label
Intellia Therapeutics Intellia Therapeutics
rdfs:comment
Intellia Therapeutics is a clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. To fully realize the transformative potential of CRISPR-based technologies, Intellia is pursuing two primary approaches. The company’s in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia’s ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases. Intellia Therapeutics Inc. ist ein US-amerikanisches Pharmaunternehmen mit Sitz in Cambridge (Massachusetts), Vereinigte Staaten. Der Hauptzweck des Unternehmens ist die Bearbeitung von Genomen.
foaf:name
Intellia Therapeutics
dbp:name
Intellia Therapeutics
foaf:depiction
n14:Intellia_Therapeutics_logo.png
dct:subject
dbc:Biotechnology_companies_of_the_United_States dbc:2014_establishments_in_the_United_States dbc:Health_care_companies_based_in_Massachusetts dbc:Pharmaceutical_companies_of_the_United_States dbc:Companies_listed_on_the_Nasdaq dbc:Companies_based_in_Cambridge,_Massachusetts dbc:Pharmaceutical_companies_established_in_2014
dbo:wikiPageID
55924239
dbo:wikiPageRevisionID
1122545627
dbo:wikiPageWikiLink
dbr:Drug_delivery dbr:Drug_development dbr:Beta_thalassemia dbc:Pharmaceutical_companies_established_in_2014 dbr:Jennifer_Doudna dbc:Health_care_companies_based_in_Massachusetts dbr:Sickle_cell_disease dbr:Cambridge,_MA dbc:Pharmaceutical_companies_of_the_United_States dbr:AbbVie dbr:Russell_2000_Index dbr:Derrick_Rossi dbr:Agios_Pharmaceuticals dbr:Atlas_Venture dbr:Hematopoetic_stem_cells dbr:Drug_target dbr:Rachel_Haurwitz dbr:Biotechnology dbr:CRISPR_gene_editing dbr:Generation_Bio_Company dbr:Vilnius_University dbc:Companies_listed_on_the_Nasdaq dbr:Biopharmaceuticals dbr:CRISPR dbr:CAR-T dbr:Rodolphe_Barrangou dbr:Caribou_Biosciences dbr:Bioinformatics dbr:Transthyretin_amyloidosis dbr:Novartis dbr:Regeneron_Pharmaceuticals dbr:CEO dbc:Companies_based_in_Cambridge,_Massachusetts dbr:Biopharmaceutical dbr:Virginijus_Šikšnys dbr:Public_company dbc:Biotechnology_companies_of_the_United_States dbc:2014_establishments_in_the_United_States dbr:Luciano_Marraffini
dbo:wikiPageExternalLink
n9:d41586-020-02765-9
owl:sameAs
dbpedia-de:Intellia_Therapeutics wikidata:Q54621387 dbpedia-fa:اینتلی_تراپیوتیکس n20:6joyH
dbp:wikiPageUsesTemplate
dbt:Reflist dbt:Page_needed dbt:Small dbt:Infobox_company dbt:Url dbt:Short_description dbt:Increase
dbo:thumbnail
n14:Intellia_Therapeutics_logo.png?width=300
dbp:foundation
2014
dbp:industry
dbr:Biopharmaceutical
dbp:keyPeople
Glenn Goddard John Leonard James Basta Laura Sepp-Lorenzino David Lebwohl
dbp:locationCity
dbr:Cambridge,_MA
dbp:locationCountry
United States
dbp:logo
Intellia_Therapeutics_logo.png
dbp:numEmployees
485
dbp:revenue
5.8E7
dbp:tradedAs
dbr:Russell_2000_Index NASDAQ:NTLA
dbp:type
dbr:Public_company
dbo:abstract
Intellia Therapeutics is a clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. To fully realize the transformative potential of CRISPR-based technologies, Intellia is pursuing two primary approaches. The company’s in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia’s ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases. The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, (with colleagues at University of California, Berkeley) and Virginijus Šikšnys (with colleagues at Vilnius University). The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics. Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies. NTLA-2002 is an investigational CRISPR therapy candidate for the treatment of hereditary angioedema (HAE) currently in Phase 1 / 2 studies. Intellia’s proprietary non-viral gene knock out platform deploys lipid nanoparticles to deliver to the liver a two-part genome editing system: guide RNA specific to the disease-causing gene and messenger RNA that encodes the Cas9 enzyme, which carries out the precision editing.Intellia also has a number of research programs for in vivo and ex vivo therapeutic candidates with potential applications in diseases including cancer, alpha-1 antitrypsin deficiency, and hemophilia. The company is also working on a variety of additional gene editing technologies including base editing and DNA writing. Intellia Therapeutics Inc. ist ein US-amerikanisches Pharmaunternehmen mit Sitz in Cambridge (Massachusetts), Vereinigte Staaten. Der Hauptzweck des Unternehmens ist die Bearbeitung von Genomen.
prov:wasDerivedFrom
wikipedia-en:Intellia_Therapeutics?oldid=1122545627&ns=0
dbo:wikiPageLength
17732
dbo:foundingYear
2014-01-01
dbo:numberOfEmployees
485
dbo:revenue
5.8E7
dbo:industry
dbr:Biopharmaceutical
dbo:type
dbr:Public_company
foaf:isPrimaryTopicOf
wikipedia-en:Intellia_Therapeutics